Housing Boosts Home...
Health Care: Drugs
AEterna Zentaris Inc. (AEZS: NASDAQ)
$2.08 0.02 | 0.97%
05/21/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -20.41M | -27.07M | -23.22M | -24.72M |
| Operating Gains/Losses | 949.00K | -2.77M | -742.00K | 1.10M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 383.00K | -3.33M | -2.03M | 1.10M |
| (Increase) Decrease in Inventories | -560.00K | -261.00K | 896.00K | -864.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.84M | 2.97M | -2.10M | -1.97M |
| (Decrease) Increase In Other Current Liabilities | -254.00K | 105.00K | -900.00K | 123.00K |
| (Increase) Decrease In Other Working Capital | -413.00K | 8.13M | -206.00K | -406.00K |
| Other Non-Cash Items | -4.95M | -1.20M | -1.06M | 1.64M |
| Net Cash From Continuing Operations | -30.82M | -26.24M | -31.12M | -24.14M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -30.82M | -26.24M | -31.12M | -24.14M |
| Sale of Property, Plant & Equipment | 0.00 | 26.00K | 32.00K | 6.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 3.24M | 0.00 | 553.00K |
| Purchases of Property, Plant & Equipment | -272.00K | -805.00K | -82.00K | -790.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -866.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -272.00K | 2.46M | -50.00K | -1.10M |
| Issuance of Debt | 0.00 | 0.00 | -59.00K | -51.00K |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 24.26M | 38.62M | 25.50M | 14.26M |
| Repayment of Long-Term Debt | -57.00K | -61.00K | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 24.21M | 38.56M | 25.44M | 14.20M |
| Effect of Exchange Rate Changes | -481.00K | 107.00K | -369.00K | -96.00K |
| Net Change in Cash & Cash Equivalents | -7.36M | 14.88M | -6.10M | -11.13M |
Portfolios with AEZS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- UserMillion Dollar Portfolio
- Userwright stocks
- UserSMITTY
- UserFiuza 1
- Userherb's portfolio
- Contributor10 Pharma Stocks Under $3
Latest AEZS Headlines from TheStreet
- 5 Stocks Under $10 Ready to Soar Higher 02.07.13 | 01:02 pm
- Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin 01.25.13 | 07:01 am
- 5 Biotech Stocks Rising on Unusual Volume 11.20.12 | 02:11 pm
- 5 Stocks Under $10 Set to Soar 09.20.12 | 01:09 pm
- Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold 09.14.12 | 06:09 am
- 2012 Biotech Stock Predictions: An Interim Report Card 08.28.12 | 07:08 am
- ASCO '12 Stocks: Winners and Losers 06.04.12 | 06:06 am
- ASCO '12: Colon Cancer Drugs Good (Roche) and Very Bad (Keryx Pharma) 06.03.12 | 06:06 am
- Keryx: Lessons From a Drug Failure 04.02.12 | 12:04 pm
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 04.02.12 | 09:04 am
Press Releases for AEZS
- Aeterna Zentaris Announces "At-the-Market" Issuance Program - PR Newswire 05.21.13 | 04:05 pm
- Aeterna Zentaris To Present At Upcoming Bloom Burton & Co. Healthcare Investor Conference In Toronto - PR Newswire 05.15.13 | 07:05 am
- Aeterna Zentaris To Announce First Quarter 2013 Financial And Operating Results On May 7, 2013 And Hold Annual Shareholders Meeting On May 8, 2013 - PR Newswire 05.01.13 | 07:05 am
- Aeterna Zentaris Newly Appointed CEO, David A. Dodd, To Host Introductory Analyst And Investor Conference Call On Thursday, April 25, 2013 - PR Newswire 04.23.13 | 04:04 pm
- Aeterna Zentaris Announces Transfer Of Manufacturing Rights Related To Cetrotide® To Merck KGaA - PR Newswire 04.17.13 | 07:04 am
- David A. Dodd Appointed President & Chief Executive Officer Of Aeterna Zentaris Inc. - PR Newswire 04.15.13 | 08:04 am
- Aeterna Zentaris Presents Encouraging Updated Data On Its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates At AACR Meeting - PR Newswire 04.10.13 | 04:04 pm
- Aeterna Zentaris And Ergomed Sign Co-Development And Profit Sharing Agreement For AEZS-108 In Endometrial Cancer - PR Newswire 04.10.13 | 07:04 am
- Aeterna Zentaris To Present At Upcoming Roth 25th Annual OC Growth Stock Conference - PR Newswire 03.13.13 | 07:03 am
- Aeterna Zentaris To Discontinue Phase 3 Trial In Multiple Myeloma With Perifosine Following Data Safety Monitoring Board Recommendation - PR Newswire 03.11.13 | 11:03 am
Partner Headlines for AEZS
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 11.05.12 | 09:11 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.01.12 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 10.19.12 | 09:10 am
- Aeterna Zentaris Announces Closing of $16.5 Million Public Offering of Common Shares and Warrants - Benzinga 10.17.12 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.16.12 | 09:10 am
- Pre-Market Most Active for Oct 12, 2012 : BAC, AMD, S, JPM, WFC, BCS, CLWR, ASML, NPSP, QQQ, SIRI, AEZS - NASDAQ 10.12.12 | 12:10 pm
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
